Loading patent…
AssigneeThe University of North Carolina at Chapel Hill
InventorsCharles Askew, Chengwen Li, Brian Kuhlman, David Forrest Thieker
Estimating the term…
This invention relates to methods and compositions for binding antibodies. The methods may be used to isolate antibodies, treat disorders related to excess antibodies, acutely block antibodies to stop an autoimmune or inflammatory response, and inhibit neutralizing antibodies. In embodiments, the invention relates to methods of inhibiting neutralizing antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of Mycoplasma protein M or a functional fragment or derivative thereof, thereby inhibiting neutralization of the heterologous agent. The invention further relates to modified Mycoplasma protein M or functional fragments thereof having increased thermostability relative to wild-type protein M and their use in the methods of the invention.
A modified Mycoplasma protein M or a functional fragment thereof, having one or more amino acid mutations that increase or maintain pH stability or thermostability of the Mycoplasma protein M or a functional fragment thereof relative to wild-type Mycoplasma protein M or a functional fragment thereof, wherein thermostability is maintained up to 75 degrees, 70 degrees, 65 degrees, 60 degrees, 55 degrees, 50 degrees, 45 degrees, 40 degrees, or 38 degrees and/or wherein pH stability is maintained from a pH of 2 to 8, from a pH of 2.5 to 7.5, or from a pH of 4.5 to 7.5.
A modified Mycoplasma protein M or a functional fragment thereof, having a deletion from about residue 185 to about residue 342 of M. genitalium protein M (SEQ ID NO:1) or the equivalent residues of another Mycoplasma protein M.
16-18. (canceled)
20-39. (canceled)
41-46. (canceled)
48-49. (canceled)
51-53. (canceled)
55-105. (canceled)
Dependencies are inferred from the claim text.